OBJECTIVE: Fatigue is among the most distressing symptoms across the breast cancer continuum. However, little is known about the factors contributing to long-term persisting fatigue. Therefore, we explored determinants of long-term physical, affective, and cognitive fatigue in a prospective cohort of breast cancer patients. METHODS: Breast cancer patients recruited in a population-based case-control study (MARIE study) provided comprehensive data on sociodemographics, lifestyle, and preexisting medical conditions. At follow-up (median 6.3 years post-diagnosis, MARIEplus), disease-free cancer survivors (N = 1928) reported current fatigue using a validated multidimensional questionnaire. Additionally, survivors retrospectively rated their fatigue levels before diagnosis, during the treatment phase, and 1 year post-surgery. Linear regression analyses were performed. RESULTS: As major determinants of long-term physical, affective, and cognitive fatigue, multiple regression analyses revealed preexisting psychological or depressive disorders, migraine, analgesic use, peripheral arterial obstructive disease (PAOD), and arthritis. A physically inactive lifestyle and obesity were associated with persisting physical fatigue. Aromatase inhibitors were also associated with long-term fatigue, especially cognitive fatigue. Chemotherapy and, to a lower extent, radiotherapy were major contributors to the development of fatigue during the treatment phase, yet were not associated with long-term fatigue. CONCLUSIONS: Although the development of fatigue in breast cancer patients seems largely impacted by cancer therapy, for the long-term persistence of fatigue, preexisting medical or psychological conditions related to depression or pain and lifestyle factors appear to be more relevant. Physicians, psycho-oncologists, and researchers may need to distinguish between acute fatigue during therapy and long-term persisting fatigue with regard to its pathophysiology and treatment.
OBJECTIVE:Fatigue is among the most distressing symptoms across the breast cancer continuum. However, little is known about the factors contributing to long-term persisting fatigue. Therefore, we explored determinants of long-term physical, affective, and cognitive fatigue in a prospective cohort of breast cancerpatients. METHODS:Breast cancerpatients recruited in a population-based case-control study (MARIE study) provided comprehensive data on sociodemographics, lifestyle, and preexisting medical conditions. At follow-up (median 6.3 years post-diagnosis, MARIEplus), disease-free cancer survivors (N = 1928) reported current fatigue using a validated multidimensional questionnaire. Additionally, survivors retrospectively rated their fatigue levels before diagnosis, during the treatment phase, and 1 year post-surgery. Linear regression analyses were performed. RESULTS: As major determinants of long-term physical, affective, and cognitive fatigue, multiple regression analyses revealed preexisting psychological or depressive disorders, migraine, analgesic use, peripheral arterial obstructive disease (PAOD), and arthritis. A physically inactive lifestyle and obesity were associated with persisting physical fatigue. Aromatase inhibitors were also associated with long-term fatigue, especially cognitive fatigue. Chemotherapy and, to a lower extent, radiotherapy were major contributors to the development of fatigue during the treatment phase, yet were not associated with long-term fatigue. CONCLUSIONS: Although the development of fatigue in breast cancerpatients seems largely impacted by cancer therapy, for the long-term persistence of fatigue, preexisting medical or psychological conditions related to depression or pain and lifestyle factors appear to be more relevant. Physicians, psycho-oncologists, and researchers may need to distinguish between acute fatigue during therapy and long-term persisting fatigue with regard to its pathophysiology and treatment.
Authors: Francisco Álvarez-Salvago; Noelia Galiano-Castillo; Manuel Arroyo-Morales; Mayra Cruz-Fernández; Mario Lozano-Lozano; Irene Cantarero-Villanueva Journal: Support Care Cancer Date: 2018-05-05 Impact factor: 3.603
Authors: Patricia M Kluding; Mamatha Pasnoor; Rupali Singh; Linda J D'Silva; Min Yoo; Sandra A Billinger; Joseph W LeMaster; Mazen M Dimachkie; Laura Herbelin; Douglas E Wright Journal: Phys Ther Date: 2014-10-02
Authors: Martina E Schmidt; Joachim Wiskemann; Theron Johnson; Nina Habermann; Andreas Schneeweiss; Karen Steindorf Journal: Support Care Cancer Date: 2018-02-14 Impact factor: 3.603
Authors: Diana M Norden; Raymond Devine; Sabahattin Bicer; Runfeng Jing; Peter J Reiser; Loren E Wold; Jonathan P Godbout; Donna O McCarthy Journal: Physiol Behav Date: 2014-12-30
Authors: Cynthia Owusu; Nora L Nock; Paul Hergenroeder; Kristina Austin; Elizabeth Bennet; Stephen Cerne; Halle Moore; Jean Petkac; Mark Schluchter; Kathryn H Schmitz; Monica Webb Hooper; Lindsay Atkins; Oghenerukeme Asagba; Leonard Wimbley; Nathan A Berger Journal: Contemp Clin Trials Date: 2020-04-15 Impact factor: 2.226
Authors: Jennifer Y Sheng; Dipali Sharma; Gerald Jerome; Cesar Augusto Santa-Maria Journal: Oncology (Williston Park) Date: 2018-08-15 Impact factor: 2.533
Authors: Marina M Reeves; Caroline O Terranova; Jane M Erickson; Jennifer R Job; Denise S K Brookes; Nicole McCarthy; Ingrid J Hickman; Sheleigh P Lawler; Brianna S Fjeldsoe; Genevieve N Healy; Elisabeth A H Winkler; Monika Janda; J Lennert Veerman; Robert S Ware; Johannes B Prins; Theo Vos; Wendy Demark-Wahnefried; Elizabeth G Eakin Journal: BMC Cancer Date: 2016-10-28 Impact factor: 4.430